{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-002260","form_type":"8-K","ticker":null,"cik":"0001318641","company_name":"Statera Biopharma, Inc.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.372591+00:00","generated_at":"2026-06-20T03:33:45.930907+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Statera declares Series B Preferred dividend with super-voting rights for share increase and reverse split","bullets":["Declared dividend of 1/1,000th share of Series B Preferred per common share; record date Feb 1, 2023.","Series B carries 1,000 votes per share, voting only on Authorized Share Increase (150M to 250M) and Reverse Split (1-for-10 to 1-for-300).","Unvoted Series B shares automatically redeemed before meeting at $0.005 per whole share (with rounding exclusions).","Bylaws amended to reduce stockholder quorum from majority to 33.34% of votes entitled to be cast."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-002260","json":"https://secwatch.observer/filing/0001437749-23-002260.json","markdown":"https://secwatch.observer/filing/0001437749-23-002260.md","text":"https://secwatch.observer/filing/0001437749-23-002260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1318641/000143774923002260/0001437749-23-002260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1318641/000143774923002260/cbli20230131_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:33:45.930907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94ba22cf41da98156159cc3d0aeea7d63887375a","claim":"Statera Biopharma, Inc.: Established Series B Preferred Stock and filed Certificate of Designation setting forth preferences, rights, and limitations (effective 2023-01-26).","evidence_excerpt":"On January 26, 2023, the board of directors (the \"Board\") of Statera Biopharma, Inc. (the \"Company\") declared a dividend of one one-thousandth of a share of Series B Preferred Stock, par value $0.005 per share (\"Series B Preferred Stock\"), for each outstanding share of the Company's common stock, par value $0.005 per share (\"Common Stock\") to stockholders of record at 5:00 p.m. Eastern Time on February 1, 2023 (the \"Record Date\"). Series B Certificate of Designation The preferences, rights, limitations and other matters relating to the Series B Preferred Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (the \"Certificate of Designation\").","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1318641/000143774923002260/0001437749-23-002260-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-01-26"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}